Revenue: As of FY2025 Q1, the actual value is USD 3.321 M.EPS: As of FY2025 Q1, the actual value is USD -0.24.EBIT: As of FY2025 Q1, the actual value is USD -1.101 M.<h3>Technology Segment</h3><ul><li>Revenues: $2,123,871 for the three months ended March 31, 2025, compared to $1,620,995 for the same period in 2024, reflecting a significant increase due to new contracts and market expansion.</li><li>Cost of Revenues: $1,074,124, leading to a gross margin of $1,049,747.</li><li>Operating Loss: - $354,237, primarily due to increased compensation and general administrative expenses.</li></ul><h3>Telehealth Segment</h3><ul><li>Revenues: $1,197,614 for the three months ended March 31, 2025, with significant contributions from patient fees ($711,264) and telehealth fees ($483,850).</li><li>Cost of Revenues: $387,390, resulting in a gross margin of $810,224.</li><li>Operating Loss: - $583,174, driven by high compensation and administrative costs.</li></ul><h3>Cash Flow</h3><ul><li>Operating Cash Flow: Net cash used in operating activities was - $440,493 for the three months ended March 31, 2025, compared to $579,286 provided in the same period in 2024, reflecting increased operating expenses and changes in working capital.</li><li>Investing Cash Flow: - $11,873 used for the purchase of fixed assets.</li><li>Financing Cash Flow: $536,373 provided, primarily from proceeds of new notes issued.</li></ul><h3>Future Outlook and Strategy</h3><ul><li>Core Business Focus: The company plans to leverage its telehealth platform to expand within the market and attract new customers, focusing on innovation and new product offerings to meet the growing demand for telehealth services.</li><li>Non-Core Business: The company is exploring additional financing options to support its working capital needs and fund growth initiatives, including negotiations for new investor financing and utilizing an equity line of credit agreement.</li></ul>

VSee Health | 10-Q: FY2025 Q1 Revenue: USD 3.321 M